Adaptive Biotechnologies Corp

Company Profile

Adaptive Biotechnologies Corp had its IPO on 2019-06-27 under the ticker symbol ADPT.

The company operates in the Healthcare sector and Biotechnology industry. Adaptive Biotechnologies Corp has a staff strength of 790 employees.

Stock update

Shares of Adaptive Biotechnologies Corp opened at $6.2 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $6.14 - $6.85, and closed at $6.67.

This is a +7.06% increase from the previous day's closing price.

A total volume of 1,308,511 shares were traded at the close of the day’s session.

In the last one week, shares of Adaptive Biotechnologies Corp have slipped by -2.06%.

Adaptive Biotechnologies Corp's Key Ratios

Adaptive Biotechnologies Corp has a market cap of $1.28 billion, indicating a price to book ratio of 2.4361 and a price to sales ratio of 6.6383.

In the last 12-months Adaptive Biotechnologies Corp’s revenue was $185.31 million with a gross profit of $-13657000 and an EBITDA of $-177666000. The EBITDA ratio measures Adaptive Biotechnologies Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Adaptive Biotechnologies Corp’s operating margin was -107.17% while its return on assets stood at -13.95% with a return of equity of -37.52%.

In Q4, Adaptive Biotechnologies Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 45.5%.

Adaptive Biotechnologies Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-1.38 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Adaptive Biotechnologies Corp’s profitability.

Adaptive Biotechnologies Corp stock is trading at a EV to sales ratio of 4.6977 and a EV to EBITDA ratio of -3.9062. Its price to sales ratio in the trailing 12-months stood at 6.6383.

Adaptive Biotechnologies Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$856.62 million

Total Liabilities

$109.79 million

Operating Cash Flow

$-97544000.00

Capital Expenditure

$2.54 million

Dividend Payout Ratio

0%

Adaptive Biotechnologies Corp ended 2024 with $856.62 million in total assets and $0 in total liabilities. Its intangible assets were valued at $856.62 million while shareholder equity stood at $464.17 million.

Adaptive Biotechnologies Corp ended 2024 with $0 in deferred long-term liabilities, $109.79 million in other current liabilities, 14000.00 in common stock, $-919082000.00 in retained earnings and $118.97 million in goodwill. Its cash balance stood at $90.03 million and cash and short-term investments were $498.20 million. The company’s total short-term debt was $9,230,000 while long-term debt stood at $0.

Adaptive Biotechnologies Corp’s total current assets stands at $562.15 million while long-term investments were $0.00 and short-term investments were $408.17 million. Its net receivables were $40.06 million compared to accounts payable of $8.08 million and inventory worth $14.45 million.

In 2024, Adaptive Biotechnologies Corp's operating cash flow was $-97544000.00 while its capital expenditure stood at $2.54 million.

Comparatively, Adaptive Biotechnologies Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$6.67

52-Week High

$15.19

52-Week Low

$5.955

Analyst Target Price

$12.29

Adaptive Biotechnologies Corp stock is currently trading at $6.67 per share. It touched a 52-week high of $15.19 and a 52-week low of $15.19. Analysts tracking the stock have a 12-month average target price of $12.29.

Its 50-day moving average was $6.88 and 200-day moving average was $7.8 The short ratio stood at 4.09 indicating a short percent outstanding of 0%.

Around 167.3% of the company’s stock are held by insiders while 9044.1% are held by institutions.